Furthermore, recent data suggests that IRAK4 inhibition synergizes with inhibition of other B-cell receptor signaling pathways, like BTK ( here).

FORBES: Immunokinase Drug Candidates: $12B in Value Creation and Counting

In December, it completed a merger with Aclara Biosciences, which is looking at differences between normal and cancer cells to determine which signaling pathways a cancer cell is exploiting for replication.

FORBES: Pioneering Personalized Medicine